ArticleCNS neuroscience & therapeutics2026
STXBP1 Variants Associated With Epilepsy With Variable Severity.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionPathogenic variants in STXBP1 are a well-established cause of developmental and epileptic encephalopathy (DEE), whereas their contribution to milder epilepsy phenotypes remains under-characterized. We sought to delineate STXBP1 variants across a clinical severity spectrum and to explore molecular correlates of phenotypic heterogeneity.
methodsTrio-based whole-exome sequencing was performed in patients with unexplained epilepsy recruited from multiple epilepsy centers. Variants were confirmed by Sanger sequencing and interpreted using ACMG criteria. Missense variants were assessed using structural modeling and biophysical prediction tools, and their effects on Munc18-1 expression were evaluated by immunoblotting in transfected HEK293T cells.
resultsEight STXBP1 variants were identified in eight unrelated cases, including one truncating variant (Lys63Ter) and seven missense variants. Five de novo missense variants (Pro187Leu, Arg190Gln, Ala251Thr, Arg292His, and Gly544Val) and one de novo truncating variant were observed exclusively in individuals with DEE. In contrast, Gly236Val segregated in a family with epilepsy with febrile seizures plus, and Pro434Leu was inherited in a family with self-limited epilepsy with centrotemporal spikes with incomplete penetrance. In silico analyses suggested that Gly236Val and Pro434Leu had comparatively milder destabilizing effects and were located at more solvent-accessible positions than DEE-associated variants. Consistently, immunoblotting showed markedly reduced Munc18-1 levels for DEE-associated missense variants, whereas Gly236Val and Pro434Leu preserved similar Munc18-1 levels to wild-type expression.
conclusionsSTXBP1 variants may underlie epilepsies of variable severity, extending from milder epilepsy syndromes to DEE. Clinical severity broadly tracks with the predicted structural/biophysical impact of the variant and Munc18-1 abundance, providing a mechanistic clue for phenotypic heterogeneity in STXBP1-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.